Retreatment of HCV Genotype-1 with Sofosbuvir and Ledipasvir after Relapse with Sofosbuvir and Ribavirin: A Pilot Study

BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV), genotype-1 (GT-1) infection for interferon-ineligible patients . However, sofosbuvir/ribavirin therapy is associated with treatment relapse in 15-30%...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Intern Med
Главные авторы: Osinusi, Anu, Kohli, Anita, Marti, Miriam M, Nelson, Amy, Zhang, Xiaozhen, Meissner, Eric G, Silk, Rachel, Townsend, Kerry, Pang, Phillip S, Subramanian, Mani, McHutchison, John G., Fauci, Anthony S, Masur, Henry, Kottilil, Shyam
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4586065/
https://ncbi.nlm.nih.gov/pubmed/25364884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/M14-1211
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы